A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Sponsor
Genentech, Inc.
Study ID
NCT00517049
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PRO95780 — DRUG
    Intravenous repeating dose
  • rituximab — DRUG
    Intravenous repeating dose

Study Details

This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has progressed following previous rituximab therapy.

Key Dates

Start date
Mar 31, 2008
Status verified
May 2017
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Objective response, as determined by independent review facility [ Time Frame: 8 months ]

Related Studies